Released Apr 15, 2026, after the close
10-K filed Apr 15, 2026, 105 days after period end · 0001213900-26-044055
Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income$4.33M$4.33M derivedno prior Q4 2024 on fileN/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$235,472—
Operating Cash Flowderived-$314,864—
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
no prior Q4 2024 on file
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Drugs Made In America Acquisition II Corp. · CIK 2040475 · Engraved from SEC EDGAR